Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=243 Atrial Fibrillation Health Literacy and Information Technology Trial
Atrial Fibrillation · Familial Atrial Fibrillation · Arrythmia, Cardiac
Primary: Proportion of Days Covered — 1.0; 0.9 Proportion of days covered — p=0.22
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
N/A N=262 iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology
Atrial Fibrillation · Atrial Flutter
Primary: Rate of Recurrence of Atrial Arrhythmias — 0.132; 0.091 episodes per person-month of follow-up — p=0.05
N/A N=41 Curing Atrial Fibrillation in Heart Failure
Chronic Heart Failure · Atrial Fibrillation
Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat
N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
N/A N=107 The Dynamics of Human Atrial Fibrillation
Atrial Fibrillation · Atrial Tachyarrhythmia
Primary: Survival Free of Atrial Fibrillation — 28; 31 participants
N/A N=53 Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
Ischemic Stroke
Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants
Phase 3 N=458 Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)
Atrial Fibrillation
Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95
N/A N=270 Atrial Fibrillation Health Literacy and Information Technology Trial in Rural Pennsylvania Counties
Atrial Fibrillation · Familial Atrial Fibrillation · Arrhythmia, Cardiac
Primary: Proportion of Days Covered — .97; 0.97 Proportion of days covered — p=0.99
N/A N=492 Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin
Stroke, Acute
Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001
N/A N=140 A New Operation for the Treatment for Long-standing Atrial Fibrillation
Cardiovascular Disease
Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants
N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
N/A N=4,658 International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)
Atrial Fibrillation
Primary: Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) — 1.3; 1.6; 1.4; 2.3 Percentage of Participants
Phase 2 N=171 Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305
Atrial Fibrillation
Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms
N/A N=80 The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…
Phase 4 N=441 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Cryptogenic Symptomatic Transient Ischemic Attack · Cryptogenic Ischemic Stroke
Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
N/A N=3,160 Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial Fibrillation · Thrombi
Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants
Phase 4 N=161 Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
Permanent Atrial Fibrillation
Primary: Patient Reported Quality of Life (SF-36) — 29.7; 31.9 score on a scale
Phase 2 N=128 Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)
Persistent or Permanent Non-valvular Atrial Fibrillation
Primary: Premature Discontinuation of Study or Study Drug Due to Any Reason — 4; 6; 3 Participants
N/A N=34 Decision Aids for Patients With Nonvalvular Chronic Atrial Fibrillation (DA4AFib)
Atrial Fibrillation
Primary: Interview Process — 34 Participants
N/A N=256 Video-based Detection of Atrial Fibrillation
Atrial Fibrillation
Primary: Area Under the Receiver Operating Characteristic Curve (AUC) for the Detection of Atrial Fibrillation — 0.74 probability
Phase 4 N=190 Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation
Atrial Fibrillation
Primary: Documented Recurrence of Atrial Fibrillation/Atrial Flutter — 59; 47 percentage of participants
N/A N=669 A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint (PSE): Event Rate of Safety Events Post Procedure — 2.3; 2.4 Percentage of participants
Phase 4 N=1,500 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Atrial Fibrillation
Primary: Number of Participants With Acute Stroke Event — 0; 6 participants — p=0.0151
Phase 2 N=523 Long-term Safety in Atrial Fibrillation Patients
Persistent or Permanent Nonvalvular Atrial Fibrillation
Primary: Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period — 55; 56 Participants
N/A N=324 Irrigated Ablation System Evaluation for Atrial Fibrillation (AF)
Paroxysmal Atrial Fibrillation
Primary: Confirmation of Entrance Block in the Pulmonary Veins — 159; 157 participants
N/A N=109 Effect of Treatment of Sleep Apnea in Patients With Paroxysmal Atrial Fibrillation
Sleep Disordered Breathing · Sleep Apnea · Paroxysmal Atrial Fibrillation
Primary: Change in AF Burden — 5.6; 5.0; 4.1; 4.3 percentage of time in AF — p=0.520
N/A N=25 AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation
Atrial Fibrillation, Persistent · Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Number of Participants With Acute Procedure Success — 13 Participants